ARTICLE | Clinical News

Bosulif: Ph III BFORE data

December 21, 2016 12:40 AM UTC

Top-line data from the open-label, international Phase III BFORE trial in 536 patients with chronic phase Ph+ CML showed that first-line treatment with once-daily 400 mg oral Bosulif met the primary e...

BCIQ Company Profiles

Avillion LLP

Pfizer Inc.

BCIQ Target Profiles

BCR-ABL tyrosine kinase